Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Fourth set of concessionary prices announced for August

The Department of Health and Social Care and the National Assembly for Wales have agreed concessionary prices for a further 12 items for August 2018 prescriptions.

This announcement is the fourth for the month, following eight prices announced on August 17, 10 on August 22 and another 18 on August 24.

Drug
Strength
Form
Price
Brimonidine
0.2%
eye drops (5)
£6.46
Buprenorphine
2mg
sugar-free sublingual tablets (7)
£4.78
Buprenorphine
8mg
sugar-free sublingual tablets (7)
£8.91
Latanoprost
50 micrograms/ml
eye drops (2.5)
£10.25
Propranolol
10mg
tablets (28)
£2.70
Propranolol
40mg
tablets (28)
£2.64
Ramipril
10mg
tablets (28)
£3.20
Risperidone
3mg
tablets (60)
£13.85
Risperidone
4mg
tablets (60)
£14.02
Risperidone
500 microgram
tablets (20)
£1.90
Tadalafil
5mg
tablets (28)
£28.37
Valsartan
40mg
capsules (28)
£5.95

Do these prices reflect the ones you have paid in July?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel